[Experimental studies on the relation of platelet activating factor (PAF) to high mortality in sublethal endotoxemia after massive hepatectomy and effects of its antagonist].
The effects of platelet activating factor antagonist (PAF-A) for sublethal endotoxemia after 70% or 84% hepatectomy in rats were studied. Endotoxin of 1mg/kg b.w. was intravenously given once on the first, third or fifth day hepatectomy. One week survival rates of 84%-hepatectomized rats with endotoxin injection on the third postoperative day was the lowest at 20%, and the lowest survival rate improved to 80% with PAF-A administration. Pathophysiology of PAF-A treated and nontreated rats with endotoxemia was investigated on the third day after 84% hepatectomy. There was no significant difference in SGOT, SGPT and blood glucose level between the two groups. PAF-A nontreated rats' prothrombin time was prolonged (p < 0.05) and serum fibrinogen level significantly decreased (p < 0.01), compared to treated rats. Platelet count distinctly decreased in both groups. Fibrin was pathologically proved in the glomeruli of the kidney in both groups. However, single cell necrosis of hepatocytes was significantly reduced by PAF-A administration. Rats without PAF-A had bloody ascites in 75% of cases and showed shock and pathologically pulmonary congestion. PAF may be related to DIC, shock, bloody ascites and high mortality rate in sublethal endotoxemia after massive hepatectomy. PAF-A was significantly effective for endotoxemia after hepatectomy.
Onuki
Y
Y
Second Department of Surgery, Hamamatsu University School of Medicine, Japan.
Nakamura
S
S
Muro
H
H
Baba
S
S
D000818:Animals; D004211:Disseminated Intravascular Coagulation / Q000209:etiology / Q000517:prevention & control; D004731:Endotoxins / Q000097:blood; D004926:Escherichia coli; D006498:Hepatectomy / Q000009:adverse effects*; D008099:Liver / Q000473:pathology; D008297:Male; D009336:Necrosis / Q000209:etiology / Q000517:prevention & control; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D012772:Shock, Septic / Q000209:etiology / Q000378:metabolism* / Q000517:prevention & control
D004731:Endotoxins; D010972:Platelet Activating Factor; D010975:Platelet Aggregation Inhibitors